Lataa...
Unanticipated Increases in Hepatic Steatosis among HIV Patients Receiving MR Antagonist Eplerenone for NAFLD
BACKGROUND & AIMS: Nonalcoholic fatty liver disease is common in HIV, but there are no approved therapies. The aim of this open-label proof-of-concept study was to determine the effect of the mineralocorticoid receptor antagonist eplerenone on hepatic fat in HIV-infected patients with hepatic fa...
Tallennettuna:
| Julkaisussa: | Liver Int |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7939026/ https://ncbi.nlm.nih.gov/pubmed/29509992 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/liv.13734 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|